VCYT
VERACYTE, INC.
Latest Form 4:Sale$197KbyEASTHAM KARIN (Director) · filed Jun 22, 2026
VERACYTE, INC. (VCYT) has 69 SEC Form 4 filings (116 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Jun 22, 2026.
The most active filer is EVP, General Counsel McGuire Annie with 8 filings. Insiders have net sold $13.3M over the trailing 6 months.
- Industry:Medical - Diagnostics & Research
- CEO:Marc Stapley
- Employees:755
- HQ:South San Francisco, CA, US
- IPO:2013-10-29
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$21.2M
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Market Cap
$3.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
EASTHAM KARINFirst in 7 months | Director | Sale | 3,729 | $197K | Jun 22 | SEC ↗ |
| EVP, General Counsel | Sale | 3,176 | $158K | Jun 5 | SEC ↗ | |
Chambers RebeccaFirst in 3 months | Chief Financial Officer | Sale | 3,561 | $177K | Jun 5 | SEC ↗ |
Stapley MarcFirst in 3 months | Chief Executive Officer | Sale | 138,051 | $6.9M | Jun 5 | SEC ↗ |
Leite JohnFirst in 3 months | Global Chief Commercial Off | Sale | 13,975 | $700K | Jun 5 | SEC ↗ |
Wygant JonathanFirst in 7 months | VP, Chief Accounting Officer | Sale | 24,000 | $1.1M | May 27 | SEC ↗ |
EPSTEIN ROBERT SFirst in 8 months | Director | Sale | 10,000 | $440K | May 22 | SEC ↗ |
| SVP, General Counsel | Sale | 10,204 | $398K | May 8 | SEC ↗ | |
Chambers RebeccaFirst in 3 months | Chief Financial Officer | Sale | 18,341 | $663K | Mar 6 | SEC ↗ |
| SVP, General Counsel | Sale | 6,658 | $237K | Mar 6 | SEC ↗ | |
| Chief Executive Officer | Sale | 45,523 | $1.6M | Mar 6 | SEC ↗ | |
Leite JohnFirst in 3 months | Chief Commercial Officer-CLIA | Sale | 5,260 | $185K | Mar 6 | SEC ↗ |
Febbo Phillip G.First in 5 months | Chief Scientific & Med Officer | Sale | 13,425 | $485K | Mar 4 | SEC ↗ |
| SVP, General Counsel | Sale | 10,739 | $463K | Dec 17 | SEC ↗ | |
| Director | Sale | 20,000 | $909K | Dec 8 | SEC ↗ | |
| SVP, General Counsel | Sale | 1,422 | $67K | Dec 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 7,668 | $361K | Dec 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 13,278 | $622K | Dec 4 | SEC ↗ | |
| Chief Commercial Officer-CLIA | Sale | 1,278 | $61K | Dec 4 | SEC ↗ | |
| Director | Sale | 1,106 | $56K | Nov 26 | SEC ↗ | |
| Chief Commercial Officer-CLIA | Sale | 2,808 | $140K | Nov 26 | SEC ↗ | |
Holstein JensFirst filing | Director | Sale | 10,000 | $424K | Nov 21 | SEC ↗ |
Wygant JonathanFirst filing | VP, Chief Accounting Officer | Sale | 5,818 | $234K | Nov 12 | SEC ↗ |
Wygant JonathanFirst filing | VP, Chief Accounting Officer | Sale | 5,102 | $216K | Nov 12 | SEC ↗ |
JONES EVAN/ FAFirst filing | Director | Sale | 43,196 | $1.9M | Nov 7 | SEC ↗ |
Chambers RebeccaFirst filing | Chief Financial Officer | Sale | 7,000 | $287K | Nov 7 | SEC ↗ |
| SVP, General Counsel | Sale | 6,466 | $259K | Nov 7 | SEC ↗ | |
EASTHAM KARINFirst filing | Director | Sale | 9,674 | $387K | Nov 7 | SEC ↗ |
Febbo Phillip G.First filing | Chief Scientific & Med Officer | Sale | 8,349 | $301K | Oct 7 | SEC ↗ |
EPSTEIN ROBERT SFirst filing | Director | Sale | 21,473 | $753K | Oct 3 | SEC ↗ |
| SVP, General Counsel | Sale | 2,160 | $76K | Oct 3 | SEC ↗ | |
Leite JohnFirst filing | Chief Commercial Officer-CLIA | Sale | 2,539 | $89K | Oct 3 | SEC ↗ |
McGuire AnnieFirst filing | SVP, General Counsel | Sale | 2,283 | $77K | Sep 23 | SEC ↗ |
Stapley MarcFirst filing | Chief Executive Officer | Sale | 7,667 | $233K | Sep 8 | SEC ↗ |
Related companies
VERACYTE, INC. is in the Healthcare sector.